Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.740954
Title: ERAP1 inhibitor development
Author: Guzanov, Pavel
ISNI:       0000 0004 7230 2905
Awarding Body: University of Oxford
Current Institution: University of Oxford
Date of Award: 2017
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
ERAP1 has been associated with a set of immune-mediated diseases, including ankylosing spondylitis. Currently, there is no selective and potent ERAP1 inhibitor available that would allow in-depth research of its functions and roles in diseases. Therefore, the aim of this work is to apply fragment-based drug design approach for the development of such inhibitor. A set of 12 structurally diverse hits was identified as a result of a screen containing 1200+ fragments using orthogonal ERAP1 activity assays. These hits can be used as a basis for development of a larger lead inhibitor, which requires structural information about their binding mode to ERAP1. Three different approaches have been tried in order to obtain such information about the binding mode. Unfortunately, ERAP1 crystallisation trials did not succeed, the potential reason being heterogeneity of the protein samples due to presence of several glycoforms. A set of 31 analogues of an IRAP inhibitor, which has been shown to inhibit ERAP1 activity, was synthesised and screened providing valuable structure-activity relationship information. Taken together, the screening campaign has resulted in a novel ERAP1 inhibitor with a single digit micromolar potency against ERAP1.
Supervisor: Brennan, Paul ; Oppermann, Udo Sponsor: Royal Commission for the Exhibition 1851
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.740954  DOI: Not available
Share: